Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Future perspectives and implications.

¹John Radcliffe Hospital, Oxford, UK.

International Journal of Clinical Practice. Supplement

|November 22, 2001

Summary

This summary is machine-generated.

Ramipril significantly reduced stroke, heart attack, and cardiovascular death in high-risk patients over 55. This ACE inhibitor offers broad cardiovascular event prevention beyond current indications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Peter Joseph Wilkinson Monks.

BMJ (Clinical research ed.)·2017

Same author

Low resting heart rates are associated with new-onset atrial fibrillation in patients with vascular disease: results of the ONTARGET/TRANSCEND studies.

Journal of internal medicine·2015

Same author

Resting heart rate is associated with renal disease outcomes in patients with vascular disease: results of the ONTARGET and TRANSCEND studies.

Journal of internal medicine·2014

Same author

Cardiovascular effects of music by entraining cardiovascular autonomic rhythms music therapy update: tailored to each person, or does one size fit all?

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·2012

Same author

Clinical value of baroreflex sensitivity.

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·2012

Same author

Physiological aspects of blood pressure measurement.

Proceedings of the Royal Society of Medicine·2010

Same journal

Comparison of tacrolimus and cyclosporin A in CYP3A5 expressing Chinese de novo kidney transplant recipients: a 2-year prospective study.

International journal of clinical practice. Supplement·2015

Same journal

Efficacy and safety of basiliximab in liver transplantation for patients with hepatitis B virus-related diseases: a single centre study.

International journal of clinical practice. Supplement·2015

Same journal

Human parvovirus B19 infection induced pure red cell aplasia in liver transplant recipients.

International journal of clinical practice. Supplement·2015

Same journal

Interleukin-2 receptor antagonist compared with antithymocyte globulin induction therapy in kidney transplantation from donors after cardiac death.

International journal of clinical practice. Supplement·2015

Same journal

Effect of CYP3A5 polymorphism on the pharmacokinetics of tacrolimus and acute rejection in renal transplant recipients: experience at a single centre.

International journal of clinical practice. Supplement·2015

Same journal

Outcomes of standard dose EC-MPS with low exposure to CsA in DCD renal transplantation recipients with DGF.

International journal of clinical practice. Supplement·2015

See all related articles

Area of Science:

Cardiology
Pharmacology
Clinical Trials

Background:

High-risk patients often have multiple cardiovascular risk factors.
Previous studies indicated potential benefits of ramipril in specific populations.

Purpose of the Study:

To evaluate the efficacy of ramipril in reducing major adverse cardiovascular events (MACE).
To assess ramipril's benefit in a broad population of elderly, high-risk individuals.

Main Methods:

Analysis of data from the HOPE, MICRO-HOPE, and SECURE trials.
Inclusion of patients over 55 with prior vascular events or diabetes plus one risk factor.
Ramipril treatment compared against placebo over 4.5 years.

Main Results:

Related Experiment Videos

Stroke incidence reduced by 32%.
Myocardial infarction incidence reduced by 20%.
Cardiovascular death incidence reduced by 25%.

Conclusions:

Ramipril provides substantial cardiovascular risk reduction in high-risk patients over 55.
Benefits are observed regardless of baseline hypertension status and are independent of other treatments.
High-dose ACE inhibition with ramipril is suitable for a wider patient group at risk of cardiovascular events.